In the context of CC, where enhanced ECM remodeling facilitates tumor invasion, angiogenesis, and immune evasion (Ii et al. 2006), MMP7’s prominent involvement in these processes, coupled with its more frequent occurrence relative to other prognostic biomarkers, provided an interesting rationale for prioritizing it as a therapeutic target. This evidence concerns the gene MMP7 and neoplasm.